Not sure about layoffs but here we go...
GSK Acquires Rapt Therapeutics for $2.2 Billion
https://www.fiercepharma.com/pharma/astellas-ceo-bd-plan-takeda-us-layoffs-chugai-chase-name-recognition
The pharma industry saw several significant developments. GSK acquired Rapt Therapeutics for $2.2 billion, primarily for a phase 2 food allergy dr-g. Takeda is laying off 243 U.S. neuroscience employees ahead of Trintellix's patent expiry. Pfizer sold its 11.7% stake in ViiV Healthcare to Shionogi for $1.9 billion. Astellas CEO stated the company will not pursue "rescue BD" despite an upcoming patent cliff. Chugai seeks greater name recognition and external partnerships as part of its long-term strategy.